Fed Circuit refuses to rehear Allergan and tribe Restasis ruling

The US Court of Appeals for the Federal Circuit yesterday, March 6, refused to rehear a decision which found Allergan and the Saint Regis Mohawk Tribe’s patents for dry-eye treatment Restasis (cyclosporine ophthalmic emulsion) are invalid.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Allergan and tribe ask for stay pending SCOTUS appeal

29 October 2018 Allergan and the Saint Regis Mohawk Tribe have urged the US Court of Appeals for the Federal Circuit to stay its ruling against them pending an appeal to the US Supreme Court.

Americas

Teva and Mylan implore Fed Circuit not to stay immunity ruling

7 November 2018 Generic makers Teva, Mylan and Akorn asked the US Court of Appeals for the Federal Circuit not to stay to its sovereign immunity ruling pending an appeal by Allergan and the Saint Regis Mohawk Tribe to the US Supreme Court.

More on this story

Americas

Allergan and tribe ask for stay pending SCOTUS appeal

29 October 2018 Allergan and the Saint Regis Mohawk Tribe have urged the US Court of Appeals for the Federal Circuit to stay its ruling against them pending an appeal to the US Supreme Court.

Americas

Teva and Mylan implore Fed Circuit not to stay immunity ruling

More on this story

Americas

Allergan and tribe ask for stay pending SCOTUS appeal

29 October 2018 Allergan and the Saint Regis Mohawk Tribe have urged the US Court of Appeals for the Federal Circuit to stay its ruling against them pending an appeal to the US Supreme Court.

Americas

Teva and Mylan implore Fed Circuit not to stay immunity ruling